← 返回

表达 TCF1 的 TIL 的免疫表型分析:可切除非小细胞肺癌中的空间分布特征及预后价值

英文原题:Immunophenotyping TCF1-expressing TILs: spatial profiling and prognostic value in operable non-small cell lung cancer.

查看英文原题

Immunophenotyping TCF1-expressing TILs: spatial profiling and prognostic value in operable non-small cell lung cancer.

PubMed 2026/01/22(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的研究结果支持一个更精细的框架,用于评估 TCF1+ TIL 以及肿瘤微环境中各细胞群体的 TCF1 表达,这对可手术 NSCLC 的预后判断具有重要意义。

研究思路结论见上方概要

TIL(肿瘤浸润淋巴细胞)(TILs)的空间分布和功能异质性显著影响非小细胞肺癌(NSCLC)患者的预后。尽管表达T细胞因子1(TCF1)的TILs已被认为是维持抗肿瘤免疫的关键因素,但其在肿瘤微环境中的亚群特征、定位及临床意义仍不明确。

我们对102例NSCLC肿瘤进行了多重免疫组化和免疫荧光检测,以表征TCF1 + 免疫细胞亚群,并分别分析肿瘤中心(TC)和浸润前沿(IF)。我们将这些数据与公开可用的单细胞RNA测序数据集及临床结局分析进行了整合。

CD4 + T细胞和CD79 + B细胞在TCF1 + 细胞群中占主导地位,而CD8 + T细胞仅占TCF1 + 免疫细胞的一小部分,尤其是在TC中。我们证实了肿瘤浸润性IgG + /IgA + 浆细胞共表达TCF1。PD1 + TCF1 - 细胞在TC和IF中均比PD1 + TCF1 + 细胞更常见,反映出终末分化耗竭型TILs在肿瘤微环境中占优势。生存分析显示,包括表达TCF1的细胞在内的TILs,其预后影响因组织定位不同而存在显著差异。多因素分析显示,TC中CD8 + TCF1 + 细胞增多(HR:2.5;p=0.039)和癌细胞TCF1表达增高(HR:2,7;p=0.041)以及IF中CD4 + TCF1 + 细胞(HR:0.4;p=0.043)分别成为无病生存期(DFS)的阴性和阳性独立预后标志物。将PD-L1表达与TILs整合分析,PD-L1免疫阳性与CD8 + 和PD1 + TCF1 - 细胞浸润增加相关,并与良好的DFS相关,尤其是在TC中。

展开英文摘要原文

The spatial distribution and functional heterogeneity of tumor-infiltrating lymphocytes (TILs) significantly impact patient outcomes in non-small cell lung cancer (NSCLC). While T cell factor 1 (TCF1) expressing TILs have emerged as key players in sustaining anti-tumor immunity, their subset characterization, localization, and clinical significance within the tumor microenvironment remain poorly defined. METHOD: We performed multiplex immunohistochemistry and immunofluorescence to characterize TCF1 + immune cell subsets, in 102 NSCLC tumors, separately analyzing the tumor center (TC) and invasive front (IF). We integrated this data with publicly available single-cell RNA-sequencing datasets and clinical outcome analyses.

CD4 + T cells and CD79 + B cells, dominate the TCF1 + landscape, while CD8 + T cells constitute a minority of TCF1 + immune cells, particularly in the TC. We demonstrated the presence of tumor-infiltrating IgG + /IgA + plasma cells co-expressing TCF1. PD1 + TCF1 - cells were more frequent than PD1 + TCF1 + cells both in the TC and IF, reflecting that terminally differentiated exhausted TILs predominate within the tumor microenvironment. Survival analyses revealed significantly different prognostic impact of TILs including TCF1-expressing cells based on topography. Multivariate analysis showed that increased CD8 + TCF1 + cells (HR: 2.5; p=0.039) and increased TCF1 expression by cancer cells (HR: 2,7; p=0.041) in the TC and CD4 + TCF1 + cells (HR: 0.4; p=0.043) in the IF emerged as negative and positive independent prognostic markers for Disease-free survival (DFS), respectively. Integrating PD-L1 expression with TILs, PD-L1 immunopositivity was correlated with increased CD8 + and PD1 + TCF1 - cell infiltration and was associated with favorable DFS especially in the TC.

Our findings support a more refined framework for TCF1 + TIL assessment and TCF1 expression across cellular populations in the tumor microenvironment, with implications for prognostication in operable NSCLC.

论文信息

作者
Ntostoglou K、Christodoulopoulos G、Stoker K、Descarpentrie J、Xagara A、Chatzidaki D、Anastasopoulou V、Nikas IP
第一作者单位
Hellenic Oncology Research Group (HORG), Athens, Greece.Greece
通讯作者单位
2nd Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Greece
期刊
Frontiers in immunology2026
原文标识
PubMed 41659881 · DOI 10.3389/fimmu.2026.1731337